Taysha Gene Therapies, Inc. (TSHA) - Stock Analysis
Last updated: Jan 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Taysha Gene Therapies displays near-term hot idea potential driven by FDA Breakthrough Therapy designation, upcoming pivotal trial data, and a strong cash runway through 2028. Technical momentum is strong with a 42% gain over 21 days but overbought conditions suggest possible short-term consolidation. The substantial regulatory catalysts provide a clear short-term growth narrative.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠No revenue ⢠Ongoing burn TSHA's liquidity and leverage have materially improved (cash ~$300M, current ratio 10.5, debt/equity ~0.45) but the company still has zero recent revenue, negative margins and persistent cash burn despite narrowing losses.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Support holding ⢠Resistance range Support Level: $4.85â$4.90 Resistance Level: $5.30â$5.90 TSHA has weakened over the last month from highs near $5.80â$5.90 (and a recent peak around $5.31) to about $4.90, holding short-term support near $4.85â$4.90 while facing bearish resistance above $5.30â$5.90.
Sentiment & News
Key News Insights: ⢠Moderate buy consensus ⢠First-patient dosed ⢠REVEAL pivotal trial Taysha got a "Moderate Buy" consensus and advanced its TSHA-102 Rett pivotal trial by dosing the first patient, signaling modest analyst confidence and tangible clinical progress.
AI Summary
TSHA has shifted into a binary, catalyst-driven investment where near-term value hinges on TSHAâ102's 6âmonth REVEAL interim responder readout and timely PPQ/manufacturing to enable a BLAâmonitor the interim results, PPQ timeline/costs, and any equity issuance cadence closely as those three factors will determine survival versus dilutive financing.
Description
Taysha Gene Therapies, Inc. is a clinical-stage company developing adeno-associated virus (AAV) gene therapies to treat monogenic disorders of the central nervous system. Its pipeline includes candidates targeting rare pediatric conditions such as giant axonal neuropathy, Rett syndrome, CLN1 disease, SLC13A5 deficiency and GM2 gangliosidosis. The company maintains a development and commercialization collaboration with UT Southwestern Medical Center and is headquartered in Dallas, Texas, having been incorporated in 2019.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 6 | Oct 13 | TSHA | Taysha Gene Therapies, Inc. | Taysha Gene Therapies displays near-term hot idea potential driven by FDA Breakthrough Therapy designation, upcoming pivotal trial data, and a strong cash runway through 2028. Technical momentum is strong with a 42% gain over 21 days but overbought conditions suggest possible short-term consolidation. The substantial regulatory catalysts provide a clear short-term growth narrative. | Closed | +14.2% |